Overview

Safety and Efficacy of DNK333 in Atopic Dermatitis Patients

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of DNK333 in patients with atopic dermatitis suffering from pruritus, who require systemic treatment of the disease.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate